Evidence map›Paper›PMID 19861144›Full record

ArticleHuman immunology2010

Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Vincent R Bonagura, Zeying Du, Elham Ashouri, Lihui Luo, Lynda J Hatam, James A DeVoti, David W Rosenthal, Bettie M Steinberg, Allan L Abramson, David W Gjertson and 2 more

Abstract read
In one paragraph

Article in Human immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Article
  3. The Role of Killer Ig-like Receptors in Diseases from A to Z.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Vincent R BonaguraFeinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY 11030, USA. bonagura@lij.edu
Zeying Du
Elham Ashouri
Lihui Luo
Lynda J Hatam
James A DeVoti
David W Rosenthal
Bettie M Steinberg
Allan L Abramson
David W Gjertson
Elaine F Reed
Raja Rajalingam
University of California, Los Angeles · USNorthwell Health · USFeinstein Institute for Medical Research · USSchneider Children's Hospital · US

Funding

HPV-Specific, Immune Suppression in Patients with RRPR01DE017227 · NIDCR · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BONAGURA, VINCENT ROBERT · 2006 to 2017
$4.5M
Anti-MHC Effects on EndotheliumR01AI042819 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 1999 to 2014
$4.0M
NIAID NIH HHS R01 AI042819NIDCR NIH HHS R01 DE017227
6 · The paper itself

Abstract

The polymorphic killer cell immunoglobulin-like receptors (KIR) control natural killer (NK) cell response against viral infection and tumor transformation. Here we investigated if select KIR genes are associated with recurrent respiratory papillomatosis (RRP), a rare disease of the larynx and upper airway caused by human papillomaviruses (HPV)-6/11. DNA from 66 RRP patients and 195 healthy controls were characterized for KIR and HLA gene polymorphism. Patients lacking activating KIR genes 3DS1 and 2DS1 were more common in severe RRP compared with mild-moderate RRP (78.8% vs 48.5%, p = 0.019). Further, patients carrying any of the known susceptible HLA-DRB1/DQB1 alleles were more frequently negative for KIR3DS1 (p = 0.006), KIR2DS1 (p = 0.003) or KIR2DS5 (p = 0.004) compared with controls carrying any of these HLA allotypes. Nearly 80% of the patients with severe disease were missing the protective HLA-DQB1*0602 allele as well as both KIR3DS1 and KIR2DS1 genes. Phenotyping of papilloma-infiltrating mononuclear-cells revealed an elevated numbers of NK cells and CD57(+)CD4(+) T cells in KIR3DS1(-)KIR2DS1(-) patients compared with patients carrying either one or both of these KIRs. Our data suggest that NK cells expressing activating receptors KIR3DS1 and KIR2DS1 may be necessary to trigger an effective early immune response against HPV-infected targets to establish resistance to RRP development.

Indexed as

CD4-Positive T-LymphocytesFemaleGenetic Predisposition to DiseaseGenotypeHLA-DQ AntigensHLA-DQ beta-ChainsHLA-DR AntigensHLA-DRB1 ChainsHuman papillomavirus 6HumansKiller Cells, NaturalLung NeoplasmsMalePapillomaPapillomavirus InfectionsPhenotypeHLA-DQ AntigensHLA-DQB1 antigenHLA-DQ beta-ChainsHLA-DR AntigensHLA-DRB1 ChainsKIR2DS1 protein, humanReceptors, KIRReceptors, KIR3DS1

Identifiers

PMID19861144
PMCPMC2815039
OpenAlexW2012580961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.